ENLV 250117 2.50P (ENLV250117P2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ENLV250117P2500

Watchlist

1.30
0.000.00%

15min DelayTrading Dec 11 11:12 ET

0.00High0.00Low

Intraday

5D
Daily

News

Enlivex Therapeutics Ltd. Receives Approval for Phase I Trial of Allocetra in TMJ Osteoarthritis Patients
Quiver QuantitativeDec 11, 2024 08:43 ET
Express News | Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis
BenzingaDec 11, 2024 08:32 ET
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis
GlobeNewswireDec 11, 2024 08:30 ET
Express News | D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
BenzingaDec 3, 2024 09:36 ET
Express News | Elivex Therapeutics Shares Are Trading Higher After the Company Announced Interim Efficacy Data Showing Statistical Significance and Marked Improvements for Its Allocetra Trial
BenzingaDec 3, 2024 09:14 ET
Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis
BenzingaDec 3, 2024 08:32 ET

Comments

Jaguar8

Dec 11, 2024 07:36

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Wednesday, 11th December at 8:30 am
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase ...

Trytosaveabit

Dec 11, 2024 07:34

News

$Enlivex Therapeutics (ENLV.US)$ Benzinga· just
Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

Jaguar8

Dec 3, 2024 16:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

Jaguar8

Dec 3, 2024 07:34

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...

Jaguar8

Nov 20, 2024 07:05

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Adopts Bitcoin Treasury Reserve Strategy